Supernus Pharmaceuticals Financials - Benzinga

Supernus Pharmaceuticals Inc

SUPNNASDAQ

Trade with Public

Trade with Public

$42.66

-0.63-1.46%

近くで: Sep 25, 5:00 PM EST

$42.66

N/A

時間外: 4:01 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Supernus Pharmaceuticals Financials

Supernus Pharmaceuticals (SUPN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
UPDATE: Supernus Pharmaceuticals Q2 Adj. EPS $0.53 Beats $0.42 Estimate

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.42 by 26.19 percent. This is a 32.5 percent increase over earnings of $0.40 per share

Benzinga Newsdesk

PRO
Supernus Pharmaceuticals Q2 EPS $(1.01) Misses $0.07 Estimate, Sales $219.058M Beat $204.962M Estimate

Benzinga Newsdesk

PRO
Supernus Pharmaceuticals Affirms FY2026 Sales Guidance of $840.000M-$870.000M vs $862.242M Est

Supernus Pharmaceuticals (NASDAQ:SUPN) affirms FY2026 sales outlook from $840.000 million-$870.000 million to $840.000 million-$870.000 million vs $862.242 million estimate.

Benzinga Newsdesk

PRO
Supernus Pharmaceuticals Q1 EPS $(0.04) Misses $(0.01) Estimate, Sales $207.705M Beat $192.918M Estimate

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 300 percent. This is a 80.95 percent increase over losses of $(0.21) per

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

PRO
Supernus Pharmaceuticals Sees FY2026 Sales $840.000M-$870.000M vs $860.987M Est

Supernus Pharmaceuticals (NASDAQ:SUPN) sees FY2026 sales of $840.000 million-$870.000 million vs $860.987 million analyst estimate.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved